I agree, I have owned this stock for several years because of the promising initial study results. I am a physician and the Lancet results and the study results today on the platelets is truly game changing. I know the eye studies will take a couple years unless they got early approval from the FDA for compassionate care treatment. The platelet studies will now need to be tested in humans. The good thing is once these studies start it will not take long to see results. They could easily recruit hundreds to thousands of patients in a controlled study in a very short period of time and they will have initial results within days based on the life of platelets as to whether they are as effective in humans as natural platelets are. I have not sold any of my stock but I am still totally confused as to why there was not a major move up. I understand the dilution but when you talk about a market of multi billions of dollars the dilution is nothing.
News 
Market Data 
Discover 
